fashion -WSS

fashion

author：explore 2025-09-27 22:59:24 - browse：2898

Hospital power in DC — Mike Reddy for STAT

WASHINGTON — Democrats unilaterally drove major reforms to the health insurance and the pharmaceutical industries without a single Republican vote in recent years. But hospitals may be a health care giant they’re unable to confront alone.

Unlike Republicans, Democrats have seized on lowering health care costs as a politically winning issue in one election cycle after another. They have campaigned on passing health insurance reform, and then protecting it. And after 20 years, they finally delivered on a promise to empower the federal government to lower drug prices in 2022.

But the remaining elephant in the room is hospital costs, which make up the biggest share of U.S. health care spending. And Democratic leaders in Congress have shown this year that they are unable to agree on even the most incremental steps toward addressing the cost of hospital care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

WSS

Weight loss drug costs may need more research, senator suggests

Astellas still sees hope in its gene therapy after four deaths

Why Charlie Gard's case is so disturbing to Americans

A Q&A with the global head of Boehringer Ingelheim's innovation unit

AI can decode, harness the power of the humane immune system

Ransomware attacks on hospitals: Study outlines patient impact

entertainment

fashion

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Morphosys mixed study results for blood cancer drug

Peter Hotez and the public health issue of online harassment

Hospitals look to new technology to keep health care workers safe

After affirmative action ruling, medical educators look to 'holistic review'

Surge of respiratory disease in China has likely explanation

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bill would stop addiction treatment from triggering child abuse inquiry

Trump demands the U.S. pay no more for drugs than other countries … again

FDA's Woodcock to retire early next year

focus

Readout LOUD podcast: A CRISPR milestone, biotech mixology

FDA rejects Alnylam's heart disease treatment over insufficient data

When women are denied an abortion, their children fare worse than peers

Chemotherapy drug shortage eases slightly but still widespread

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Bristol 'take

hotspot

Wikipedia

entertainment

focus